europrotective effects of Memantine in ischemic stroke
Not Applicable
- Conditions
- Stroke.Stroke, not specified as haemorrhage or infarction
- Registration Number
- IRCT2012092910178N2
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
inclusion criteria: all patients with stroke
exclusion criteria: hemorrhagic stroke; sensitivity to Memantine or Statins; acute or chronic renal failure; acute or chronic hepatic disease; acute MI (<48 hours); autoimmune diseases; administration of Statin or Memantine during 6 months before stroke
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Matrix metaloproteinase 2. Timepoint: Day 1, 3, 5. Method of measurement: ELISA kits.;Matrix metaloproteinase 9. Timepoint: Day 1, 3, 5. Method of measurement: ELISA kits.
- Secondary Outcome Measures
Name Time Method Barthel index. Timepoint: 3 months after ischemic stroke. Method of measurement: Questionnaire.;Motality. Timepoint: 90 days after stroke. Method of measurement: check by phone.;National Institute for Health Stroke Score (NIHSS). Timepoint: Days 1 and 5 after stroke. Method of measurement: Questionnaire.